Thymostimulin in advanced hepatocellular carcinoma: A phase II trial

BMC Cancer

Volumn 8, Issue , 2008, Pages

  Dollinger, Matthias M ^a   Behrens, Christa M ^a   Lesske, Joachim ^a,b   Behl, Susanne ^a   Behrmann, Curd ^a   Fleig, Wolfgang E ^a,c  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b Department of Medicine   (Germany)

^c UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MITOMYCIN C; RETINOIC ACID; SOMATOSTATIN; TAMOXIFEN; THYMOPHYSIN CYTOCHEMIA; THYMOSTIMULIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; THYMUS EXTRACT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; ERYTHEMA; FEMALE; HUMAN; INJECTION SITE PAIN; LIVER CELL CARCINOMA; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROPORTIONAL HAZARDS MODEL; TREATMENT DURATION; TREATMENT RESPONSE; DISEASE COURSE; LIVER TUMOR; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; REGRESSION ANALYSIS; TIME; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROPORTIONAL HAZARDS MODELS; REGRESSION ANALYSIS; THYMUS EXTRACTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 42449106982     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-8-72     Document Type: Article

References (31)

1. Bosch FX Ribes J Díaz M Cléries R Primary liver cancer: Worldwide incidence and trends Gastroenterology 2004, 127:S5-S16. 10.1053/j.gastro.2004.09.011 15508102
2. Bruix J Llovet JM Prognostic prediction and treatment strategy in hepatocellular carcinoma Hepatology 2002, 35:519-524. 10.1053/ jhep.2002.32089 11870363
3. Fleig WE Lesske J Hepatocellular carcinoma: Primary and secondary prophylaxis as well as medical therapy Chir Gastroenterol 2003, 19:247-252. 10.1159/000074010
4. Beaugrand M N'kontchou G Seror O Ganne N Trinchet J-C Local/regional and systemic treatments of hepatocellular carcinoma Semin Liver Dis 2005, 25:201-211. 10.1055/s-2005-871199 15918148
5. Geissler M Mohr L Ali MY Grimm CF Ritter M Blum HE Immunobiology and gene-based immunotherapy of hepatocellular carcinoma Z Gastroenterol 2003, 41:1101-1110. 10.1055/s-2003-44304 14648380
6. Palmieri G Biondi E Morabito A Rea A Gravina A Bianco AR Thymostimulin treatment of hepatocellular carcinoma on liver cirrhosis Int J Oncol 1996, 8:827-832.
7. Chen C Li M Chai H Chai H Fisher W Yao QH Roles of thymosins in cancers and other organ systems World J Surg 2005, 29:264-270. 10.1007/ s00268-004-7817-2 15706436
8. Bodey B Thymic hormones in cancer diagnostics and treatment Exp Opin Biol Ther 2001, 1(1):93-107. 10.1517/14712598.1.1.93 11727550
9. Dechant KL Bryson HM Thymostimulin: A review of its pharmacology and prospective role in immunotherapy Clin Immunother 1994, 1:378-398.
10. Balch G Izzo F Chiao P Klostergaard J Curley SA Activation of human Kupffer cells by thymostimulin (TP-1) to produce cytotoxicity against human hepatocellular cancer Ann Surg Oncol 1997, 4:149-155. 10.1007/ BF02303798 9084852
11. Miller AB Hoogstraten B Staquet M Winkler A Reporting results of cancer treatment Cancer 1981, 47:207-214. 10.1002/ 1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6 7459811
12. Oken MM Creech RH Tormey DC Horton J Davis TE McFadden ET Carbone PP Toxicity and response criteria of the Eastern Cooperative Oncology Group Am J Clin Oncol 1982, 5:649-655. 10.1097/00000421-198212000-00014 7165009
13. Llovet JM Real MI Montaňa X Planas R Coll S Aponte J Ayuso C Sala M Muchart J Sola R Rodes J Bruix J Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial Lancet 2002, 359:1734-1739. 10.1016/S0140-6736(02)08649-X 12049862
14. Burroughs A Hochhauser D Meyer T Systemic treatment and liver transplantation for hepatocellular carcinoma: Two ends of the therapeutic spectrum Lancet Oncol 2004, 5:409-418. 10.1016/ S1470-2045(04)01508-6 15231247
15. Okuda K Ohtsuki T Obata H Tomimatsu M Okazaki N Hasegawa H Nakajima Y Ohnishi K Natural history of hepatocellular carcinoma and prognosis in relation to treatment: Study of 850 patients Cancer 1985, 56;918-928. 10.1002/1097-0142(19850815)56:4<918::AID-CNCR2820560437>3.0.CO;2-E 2990661
16. The Cancer of the Liver Italian Program (CLIP) Investigators Prospective validation of the CLIP score: A new prognostic system for patients with cirrhosis and hepatocellular carcinoma Hepatology 2000, 31:840-845. 10.1053/he.2000.5628 10733537
17. Llovet JM Bru C Bruix J Prognosis of hepatocellular carcinoma: The BCLC staging classification Semin Liv Dis 1999, 19(3):329-338. 10518312
18. Llovet JM Bustamante J Castells A Vilana R Ayuso MD Sala M Bru C Rodes J Bruix J Natural history of untreated nonsurgical hepatocellular carcinoma: A rationale for the design and evaluation of therapeutic trials Hepatology 1999, 29:62-67. 10.1002/hep.510290145 9862851
19. Mathurin P Rixe O Carbonell N Bernard B Cluzel P Bellin MF Khayat D Opolon P Poynard T Review article: Overview of medical treatments in unresectable hepatocellular carcinoma - an impossible meta-analysis? Aliment Pharmacol Ther 1998, 12:111-126. 10.1046/ j.1365-2036.1998.00286.x 9692685
20. Llovet JM Bruix J Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolisation improves survival Hepatology 2003, 37:429-442. 10.1053/jhep.2003.50047 12540794
21. Becker G Allgaier HP Olschewski M Zähringer A Blum HE for the HECTOR Study Group Long-acting octreotide versus placebo for treatment of advanced HCC: A randomized controlled double-blind study Hepatology 2007, 45:9-15. 10.1002/hep.21468 17187405
22. Zhu AX Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma Cancer 2008, 112:250-259. 10.1002/cncr.23175 18041064
23. Yang CH Lin WC Chuang CK Chang YC Pang ST Lin YC Kuo TT Hsieh JJ Chang JW Hand-foot skin reaction in patients treated with sorafenib: A clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy Br J Dermatol 2008, 158:592-596. 10.1111/j.1365-2133.2007.08357.x 18070211
24. Furuse J Ishii H Nakachi K Suzuki E Shimizu S Nakajima K Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma Cancer Sci 2008, 99:159-65. 17953709
25. Bolognesi M Merkel C Bianco S Angeli P Sacerdoti D Amodio P Gatta A Clinical significance of the evaluation of hepatic reticuloendothelial removal capacity in patients with cirrhosis Hepatology 1994, 19:628-634. 10.1002/hep.1840190313 8119687
26. Chuang WL Liu HW Chang WY Chen SC Hsieh MY Wang LY Natural killer cell activity in patients with liver cirrhosis relative to severity of liver damage Dig Dis Sci 1991, 36:299-302. 10.1007/BF01318200 1995265
27. Nouriaria KT Alexander GJM Portmann BC Hegarty JE Eddleston ALWF Williams R T and B cell function in alcoholic liver disease J Hepatol 1986, 2:195-207. 10.1016/S0168-8278(86)80078-2 2937833
28. Saibara T Maeda T Miyazaki M Onishi S Yamamoto Y Depressed immune function in patients with cirrhosis before emergence of hepatocellular carcinoma Hepatology 1993, 18:315-319. 7687981
29. Mustacchi G Pevise L Milani S Iaffaioli V Caraco A Comella G Contu A Farris A Attadoparinello G Narcisi M Brema F Beni A Bumma C High-dose folinic acid (FA) and fluorouracil (FU) plus or minus thymostimulin (TS) for treatment of metastatic colorectal cancer: Results of a randomized multicenter clinical trial Anticancer Res 1994, 14:617-620. 8010718
30. Federico M Gobbi P Moretti G Avanzini P Direnzo N Cavanna L Ascari E Silingardi V Effects of thymostimulin with combination chemotherapy in patients with aggressive non-Hodgkin's lymphoma Am J Clin Oncol 1995, 18:8-14. 10.1097/00000421-199502000-00002 7847265
31. Molto LM Carballido JA Manzano L Olivier C Lapuerta M Alvarezmon M Thymostimulin enhances the natural cytotoxic activity of patients with transitional cell carcinoma of the bladder Int J Immunopharmacol 1993, 15:335-341. 8505146